Incoming GlaxoSmithKline plc (NYSE: GSK) CEO Emma Walmsley got a little welcoming gift from the Food and Drug Administration the week she took the reins of the venerable British healthcare company. Mylan (NASDAQ: MYL) received a notification that its application for a generic version of Glaxo’s asthma drug Advair was not approved. Glaxo’s 2017 financials will almost certainly benefit from Mylan’s setback, but the reprieve is probably only temporary.